Cardiovascular effects.
Amylin can lower blood pressure in anesthetized animals (in which reflex bradycardia is absent), or evoke reflex bradycardia. This effect is likely in response to vasodilatation mediated via calcitonin gene-related peptide (CGRP) receptors, and only occurs at concentrations two to three orders of magnitude higher than physiological amylin concentrations. There is suggestive, but not fully established, evidence for an amylin-like pharmacology with cardiotropic effects, consisting of inotropy (stimulation of contractility) and suppression of secretion of atrial natriuretic peptide (ANP).
Amylin Pharmaceuticals, Inc., San Diego, California, USA.
Andrew
A
Young
D000682:Amyloid / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D007004:Hypoglycemic Agents / Q000494:pharmacology; D058228:Islet Amyloid Polypeptide
D000682:Amyloid; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide